Literature DB >> 7097603

Erythrocyte nucleoside transport: asymmetrical binding of nitrobenzylthioinosine to nucleoside permeation sites.

S M Jarvis, D McBride, J D Young.   

Abstract

1. Nitrobenzylthioinosine is a potent and specific inhibitor of nucleoside translocation in animal cells. Kinetic and inhibitor binding studies were undertaken to clarify how this inhibitor interacts with the nucleoside transporter from human and nucleoside-permeable type sheep erythrocytes.2. [(3)H]nitrobenzylthioinosine inhibition of zero-trans [U-(14)C]uridine influx into nucleoside-permeable type sheep cells was consistent with simple competitive inhibition (apparent K(i) 1 nmol/l). Analysis of results using total inhibitor levels instead of cell-free inhibitor concentrations did not affect the inhibition pattern, but increased the apparent K(i) value by 5-fold.3. In contrast, [(3)H]nitrobenzylthioinosine was a non-competitive inhibitor of zero-trans [U-(14)C]uridine efflux (apparent Ki 1.5 nmol/l). Dipyridamole, another potent inhibitor of nucleoside translocation, also inhibited zero-trans [U-(14)C]uridine influx in a competitive manner (apparent K(i) 20-40 nmol/l).4. [(3)H]nitrobenzylthioinosine bound to high-affinity sites on cell membranes from human and nucleoside-permeable type sheep cells (apparent K(D) values approximately 1 nmol/l). Binding of inhibitor to these sites was competitively blocked by uridine, a well characterized substrate for the nucleoside transporter (apparent K(i) 1.25 and 0.9 mmol/l, respectively). These apparent K(i) values are close to the apparent K(m) for uridine equilibrium exchange in human erythrocytes.5. Similarly, deoxycytidine was found to be a competitive inhibitor of high-affinity [(3)H]nitrobenzylthioinosine binding activity (apparent K(i) 1.0 and 1.2 mmol/l for human and nucleoside-permeable type sheep cell membranes, respectively). This contrasts with a previous report that this nucleoside had no effect on inhibitor binding activity. Transport studies confirmed that deoxycytidine is a substrate for the erythrocyte nucleoside transporter. Apparent K(m) and V(max) values for [U-(14)C]-deoxycytidine zero-trans influx into human and nucleoside-permeable type sheep cells were comparable to those obtained for [U-(14)C]uridine.6. It is suggested from these results that nitrobenzylthioinosine competes directly with nucleosides for the permeation site of the nucleoside transporter, but that inhibitor binds preferentially to the external membrane surface.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7097603      PMCID: PMC1250692          DOI: 10.1113/jphysiol.1982.sp014099

Source DB:  PubMed          Journal:  J Physiol        ISSN: 0022-3751            Impact factor:   5.182


  37 in total

1.  Binding of the nucleoside transport inhibitor 4-nitrobenzylthioinosine to erythrocyte membranes.

Authors:  M A Pickard; R R Brown; B Paul; A R Paterson
Journal:  Can J Biochem       Date:  1973-05

2.  Kinetics of adenosine uptake by erythrocytes, and the influence of dipyridamole.

Authors:  H Roos; K Pfleger
Journal:  Mol Pharmacol       Date:  1972-07       Impact factor: 4.436

3.  Use of 4-nitrobenzylthioinosine in the measurement of rates of nucleoside transport in human erythrocytes.

Authors:  M A Pickard; A R Paterson
Journal:  Can J Biochem       Date:  1972-07

4.  Mediated transport of nucleosides in human erythrocytes. Accelerative exchange diffusion of uridine and thymidine and specificity toward pyrimidine nucleosides as permeants.

Authors:  C E Cass; A R Paterson
Journal:  J Biol Chem       Date:  1972-05-25       Impact factor: 5.157

5.  Nucleoside transport. II. Inhibition by p-nitrobenzylthioguanosine and related compounds.

Authors:  A R Paterson; J M Oliver
Journal:  Can J Biochem       Date:  1971-02

6.  A simple graphical method for determining the inhibition constants of mixed, uncompetitive and non-competitive inhibitors.

Authors:  A Cornish-Bowden
Journal:  Biochem J       Date:  1974-01       Impact factor: 3.857

7.  Inhibitors of nucleoside metabolism.

Authors:  A R Paterson; A I Simpson
Journal:  Cancer Res       Date:  1967-05       Impact factor: 12.701

8.  Mediated transport of nucleosides in human erythrocytes. Specific binding of the inhibitor nitrobenzylthioinosine to nucleoside transport sites in the erythrocyte membrane.

Authors:  C E Cass; L A Gaudette; A R Paterson
Journal:  Biochim Biophys Acta       Date:  1974-04-12

9.  Inhibition of ribonucleoside metabolism in Ehrlich ascites tumor cells by purine analogue ribonucleosides.

Authors:  A R Paterson; A I Simpson
Journal:  Can J Biochem       Date:  1965-10

10.  Inosine permeability and purine nucleoside phosphorylase activity as limiting factors for the synthesis of 2,3-diphosphoglycerate from inosine, pyruvate, and inorganic phosphate in erythrocytes of various mammalian species.

Authors:  J Duhm
Journal:  Biochim Biophys Acta       Date:  1974-03-20
View more
  21 in total

1.  Selective Inhibition of Human Equilibrative and Concentrative Nucleoside Transporters by BCR-ABL Kinase Inhibitors: IDENTIFICATION OF KEY hENT1 AMINO ACID RESIDUES FOR INTERACTION WITH BCR-ABL KINASE INHIBITORS.

Authors:  Vijaya L Damaraju; Dwayne Weber; Michelle Kuzma; Carol E Cass; Michael B Sawyer
Journal:  J Biol Chem       Date:  2016-07-18       Impact factor: 5.157

2.  Characterization of monoclonal antibodies that recognize band 4.5 polypeptides associated with nucleoside transport in pig erythrocytes.

Authors:  A H Good; J D Craik; S M Jarvis; F Y Kwong; J D Young; A R Paterson; C E Cass
Journal:  Biochem J       Date:  1987-06-15       Impact factor: 3.857

3.  Functional production and reconstitution of the human equilibrative nucleoside transporter (hENT1) in Saccharomyces cerevisiae. Interaction of inhibitors of nucleoside transport with recombinant hENT1 and a glycosylation-defective derivative (hENT1/N48Q).

Authors:  M F Vickers; R S Mani; M Sundaram; D L Hogue; J D Young; S A Baldwin; C E Cass
Journal:  Biochem J       Date:  1999-04-01       Impact factor: 3.857

4.  Nucleoside transport in rat erythrocytes: two components with differences in sensitivity to inhibition by nitrobenzylthioinosine and p-chloromercuriphenyl sulfonate.

Authors:  S M Jarvis; J D Young
Journal:  J Membr Biol       Date:  1986       Impact factor: 1.843

5.  Identification of Cys140 in helix 4 as an exofacial cysteine residue within the substrate-translocation channel of rat equilibrative nitrobenzylthioinosine (NBMPR)-insensitive nucleoside transporter rENT2.

Authors:  S Y Yao; M Sundaram; E G Chomey; C E Cass; S A Baldwin; J D Young
Journal:  Biochem J       Date:  2001-01-15       Impact factor: 3.857

6.  Proteolytic cleavage of [3H]nitrobenzylthioinosine-labelled nucleoside transporter in human erythrocytes.

Authors:  N S Janmohamed; J D Young; S M Jarvis
Journal:  Biochem J       Date:  1985-09-15       Impact factor: 3.857

7.  Enhanced retention of cytosine arabinoside and its metabolites and synergistic cytotoxicity by sequential treatment with dipyridamole in L5178Y leukemia.

Authors:  J L Yang; J C White; R L Capizzi
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

8.  Kinetics of nitrobenzylthioinosine binding to the human erythrocyte nucleoside transporter.

Authors:  S M Jarvis; S N Janmohamed; J D Young
Journal:  Biochem J       Date:  1983-12-15       Impact factor: 3.857

9.  Nucleoside translocation in sheep reticulocytes and fetal erythrocytes: a proposed model for the nucleoside transporter.

Authors:  S M Jarvis; J D Young
Journal:  J Physiol       Date:  1982-03       Impact factor: 5.182

10.  Phase I trial of combination therapy of cancer with N-phosphonacetyl-L-aspartic acid and dipyridamole.

Authors:  M Markman; T C Chan; S Cleary; S B Howell
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.